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Abstract— Early stage Health Technology Assessment 
(HTA) of biomedical devices requires different methods than 
those usually employed for pharmaceuticals. This paper re-
views widely-used methods for HTA, discusses their limits for 
early stage evaluation of biomedical devices and presents two 
methods for early stage HTA being developed in the  Multidis-
ciplinary Assessment of Technology Centre for Healthcare 
(MATCH) project: Analytic Hierarchy Process (AHP) to elicit 
user needs; and early stage economic evaluations using Mar-
kov Models. 
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I. INTRODUCTION  
Health Technology Assessment (HTA) is a multidiscipli-
nary and multidimensional process useful for evaluating 
alternative and competing medical technologies. In addition 
to drugs, health technologies, following the definition of 
WHO, also includes biomedical devices, healthcare 
processes and healthcare service provision. Nonetheless, 
HTA methods can be difficult to apply to biomedical devic-
es particularly in early stage assessment. Established in 
2003, the Multidisciplinary Assessment of Technology 
Centre for Healthcare (MATCH) is a long-term research 
collaboration between four UK universities (Birmingham, 
Brunel, Nottingham & Ulster) and a cohort of industrial 
partners, also supported by stakeholders from the NHS and 
other public sector organizations (www.match.ac.uk). The 
MATCH project is focused on development of methods and 
tools for early stage HTA. This paper, after reviewing stan-
dard HTA methods, presents some methods being devel-
oped in MATCH for early stage HTA of biomedical devic-
es. This paper is structured into three sections: a brief 
review of standard methods of HTA; limits of these me-
thods for biomedical devices and for early stage HTA; two 
methods, are being investigated through MATCH projects: 
early stage economical evaluations via Markov models; 
Analytic Hierarchy process AHP to elicit user needs. 
II. HTA DE FACTO STANDARD  
The majority of published HTA reports have a regular 
structure.  This defines a de facto standard of methods and 
tools for HTA. The basic structure of many HTA reports 
can be summarized as: definition of the medical goal and 
decision problem; assessment of consequences using clini-
cal evidence; resource assessment using cost analysis; anal-
ysis of incremental cost versus consequences. 
Different scenarios may affect the decision definition 
problem. Medical goals are often driven by contingencies, 
and change according to the scale of the problem. Therefore 
it is not easy to identify a gold standard method. Although 
many authors suggest assessing the consequences of a 
health technology in several dimensions (economical, tech-
nical, ethical etc.) the majority of studies focused mainly on 
the clinical and the economical dimensions. While this is in 
theory a limitation, these two dimensions are sufficient for 
the majority of HTA studies, and these will be the only two 
considered in this paper. 
A. Consequence assessment: the clinical evidence 
The gold standard for the assessment of clinical evidence 
is the so called pyramid of evidence. According to the exist-
ing knowledge on the specific medical problem, clinical 
evidence is collected as primary data, via clinical trials, or 
synthesized as secondary data, via systematic review of 
literature. Primary data collection is usually performed via 
four different kinds of direct clinical researches of growing 
evidence: laboratory studies, case series/reports, case con-
trol studies, cohort studies, Randomized Controlled Trials 
(RCT). Systematic literature reviews synthesize and gene-
ralize outcomes of direct clinical research. At the top of the 
evidence pyramid are the systematic reviews of RCTs with 
meta-analyses. These studies, after individuating relevant 
literature using well defined research strategies and scientif-
ic databases, pool together RCT outcomes, overcoming 
contextual limitations, which otherwise reduce their evi-
dence (e.g. limited number of patients, single centre pa-
tients‟ enrolment, limited time of enrolment). The data pool-
ing is a weighted average of homogeneous RCT outcomes, 
performed using statistical methods, basing on two main 
ideas: RCT outcomes are considered more reliable 
(weighted relatively more) according to: the number of 
patients involved, the precision of its findings [1]; hetero-
geneity among RCTs, may be partially corrected using 
statistical techniques: fixed effects [1] or random ones [2]. 
Clinical consequences may be classified in three main 
groups: effectiveness, utility, benefits. Effectiveness is con-
sidered as the efficacy in real world and is measured as the 
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Table 1 Description of the principal cost-consequence analyses. 
  cost-minimization cost-effectiveness cost-utility cost-benefits 
Costs  monetary units  monetary units  monetary units  monetary units 
Consequences  equal in both programs  clinical outcomes  QALY  monetary units 
Measuring  differences in costs (C)  ICER  ICUR  ICBR 
Advantage  direct measurement 
 necessary for the other 
 direct measurement 
 uniform clinical outcomes 
 indirect measurements 
 mixed clinical outcomes  
 multidimensional analysis 
 indirect measurements 
 mixed outcomes  
 multidimensional analysis 
Limits  no consequences  one-dimensional analysis 
 data table missing in many 
national health services 
 indirect measurement 
 data table missing in many 
national health services 
 indirect measurement 
 monetization of value of life 
 ethical limits 
 
degree of satisfaction of clinical outcomes (e.g.: reduction 
of mortality, morbidity, pain, complications etc.). Utility is 
a multidimensional function of several clinical outcomes, 
used to estimate the quality of life. The basic idea is that 
two years lived at 50% are as good as 1 year at 100%. The 
quality of life is measured using several scales, which spe-
cific for pathologies or generally used for different one as 
the Quality Adjusted Life Year (QALY). In both cases the 
quality is self-assessed using a visual analog scale (VAS) 
and/or  structured questionnaires like the EQ-5D [3] asking 
to each patient to judge five dimensions (mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression) using 
three levels (no problem, some problems, severe problems), 
defining a 0-1 scale of health of 245 steps, 3
5
+2 (uncons-
cious or dead). Finally, consequences are measured as bene-
fits if they are expressed in monetary units. 
B. Resources assessment: cost analysis. 
Cost analysis consists in giving a monetary value to each 
resource used in the process of care. Many authors consider 
fixed costs and variable costs for technology under compar-
isons on a plane which has on its x-axis the number of 
treatments performed in a period of time and on the y-axis 
the costs for the treatment over that time. This become more 
complex when resources needed by each patients may vary 
according to pathology evolution (e.g. worsening may re-
quire extra resources). In fact, patients within the same 
population under assessment could be in different initial 
stages of pathology (e.g. mild, moderate, and severe) at the 
start of the study. According to each state, it may vary: the 
probability to have exacerbation (% have or not exacerba-
tion); the quality of exacerbation (% of  mild, moderate, and 
severe exacerbations); the probability to move from one 
state to another (e,g.: % of mild becoming moderate) in the 
next time-step. 
Many HTA reports employ Markov models [4] to deal 
with such scenarios. These models assume that a patient is 
always in one of a finite number of discrete health states, 
called Markov states (nodes into the model). All events are 
represented as transitions from one state to another (edges), 
with a given probability. A marginal cost is associated with 
each event „k‟, which represents the total amount of re-
quired resources required for that event, including costs for: 
normal treatment; treatment of exacerbations etc. 
C. Incremental Cost-consequence analysis 
If a new technology is proved to be less effective and 
more costly than the benchmark, it is rejected with no more 
analysis required unless there is a high degree of uncertainty 
in the data. Conversely, a technology is a good candidate for 
adoption if it more effective and less costly.  Often, howev-
er, there is an additional cost to achieving more effective-
ness. One of the principal reasons is that behind a new tech-
nology there are design and prototyping costs together with 
low volume productions, which often demand higher costs 
compared with the established product. In these cases the 
Incremental Cost Effectiveness (or Utility) Ratio (respec-
tively ICER or ICUR) has to be evaluated (table 1). An 
ICER over a given threshold may suggest that the new tech-
nology is more cost-effective, and therefore its adoption is 
justified since the expected outcomes are considered to be 
worth the costs incurred. 
Also consequences may vary, over a span of time, ac-
cording to patients‟ progression of health. Once again Mar-
kov models [4] may be used to estimate cost-consequences 
ratios in patient populations. In this case three steps are 
usually performed: 
1. Each status „k‟ of a pathology (including the initial one) 
is associated to a cost (Ck), which represents the total 
amount of required resources such trading patients in 
such status, and a marginal consequence, which may be a 
marginal effectiveness variation (Ek) or a marginal utili-
ty (Uk). 
2. The transition from one status to each another is asso-
ciated with a probability. 
3. The expected exacerbations from each state are asso-
ciated with a probability, for each kind of exacerbation 
(eg: mild or severe). 
4. The total path costs for each final state and the total path 
effectiveness (or utility) are combined representing the 
total costs (C) and total consequences (E or U) for groups 
of patients in each final state. 
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Table 2  main differences among drugs and devices impacting on HTA [6] 
Devices Drug 
Principal action  
Other than principally drugs 
Mechanical/Electromagnetic/Materials 
Pharmaco./Immunologic/Metabolic 
Chemical based 
Product life cycle  
Short life cycle 
Constantly evolving components/parts 
Long life cycle 
Unchanging compound 
Clinical evaluation  
Difficult to blind (no placebo) 
Multiple end users 
Long learning curve 
Strongly dependent by settings/users 
Complex to standardize for RCT 
Easy to blind 
Usually one end users 
Short learning curve 
Less dependent by settings/users 
Easy to standardize for RCT 
Use issues  
User-dependent efficacy 
Often require intensive training 
Complication decrease with use 
Efficacy is less user-dependent 
Usually do not require training 
Complication increase with use 
Diversity  
Mainly small companies/few large co. 
Diagnostic or therapeutic 
Mainly large multinationals 
Therapeutic 
Costs  
Varying overheads/slow return 
Higher distribution costs 
Higher maintenance/installation costs  
High overheads with quicker return 
Lower distribution costs 
No maintenance/installation 
 
5. The model is then evaluated dynamically by matrix alge-
bra, as a cohort simulation, or as a Monte Carlo simula-
tion. This generates a distribution of points (U,C)j, with 
j=1…N (number of simulations performed) on a cost-
consequence plan.  
 
In the case of a comparison of a new health technology 
(T1) with a benchmark (T0), this procedure is repeated 
using the same Markov model, but with probabilities, costs 
and consequences arising from use of the new technology to 
calculate differential costs and consequences among the two 
technologies (=T1-T0). In this case, the cost-consequence 
plane has as x-axis the differences in consequences (E or 
U) and on the y-axis the differences in costs (C). The 
final evaluation is then performed using available cost and 
consequence (usually utility) data. In this case the threshold 
boundary is the line y=x, where  is the relevant ICUR 
from historical data, where available [5]. 
III.  THE MATCH EXPERIENCE 
A. Limits of Standard methods 
The majority of HTA studies focus on evaluation of drugs, 
rather than medical devices. Therefore, the main  methods 
employed are well suited to such a scope. Nonetheless, 
there are some differences between drugs and medical de-
vices, which impact severely on HTA (Table 2). Moreover, 
HTA methods do not really inform biomedical product 
developers on the probability of return on investment, nor 
do they inform about the market needs and specific re-
quirements of technologies in development [7]. Finally, 
standard methods of HTA do not allow prioritization of user 
need. 
B. AHP to elicit user needs 
AHP is a decision-making method, which aims to solve 
multifactorial and multidimensional problems. This method 
is particularly effective in quantifying the user opinions, 
based on their personal experiences, to design a consistent 
decision framework. AHP consists of defining a hierarchy 
of elements and prioritizing them by submitting question-
naires in which each respondent, through pair-wise com-
parison, judges relative importance of elements. By posing 
redundant questions it is possible to assess the coherence of 
respondent judgments. Applying this method iteratively it is 
possible to elicit: relative importance of each need into its 
category (local weights, LW), relative importance of each 
category (category weights, CW), relative importance of 
each need compared to all the other individuated (global 
weight, GW= LW*CW). Further details on AHP can be 
found in the references [8-11]. The AHP method is effective 
in eliciting user needs, following the next 3 steps: 
1. Identification of needs, which the new biomedical de-
vices aim to satisfy. This step involves 1-2 domain ex-
perts (e.g. specialized clinicians) and potential users of 
the device. 
2. Design of a tree of needs with nodes (categories) and leaf 
(needs). Three main categories are: clinical needs, eco-
nomical needs, technical needs. This step involves 2 ex-
perts (one domain expert and one experienced in AHP). 
3. Development and submission of questionnaires to elicit 
user needs. This involves 1 expert of AHP and “n” expert 
of domain, recruited via scientific societies. 
This method was successfully applied to elicit user needs 
in previous studies: for a new CT scanner purchasing [8]; to 
choose a maintenance contract [9] according to hospital 
location and assets; identify the best model of care for heart 
failure [10], to identify risk factors for falls in elderly home 
dwelling [11]. 
C. Early stage evaluations via Markov Chain 
During development of a new device or technology innova-
tion it may be difficult to obtain data that fully considers 
stratification of patient by risk or past interventions, or to 
consider the full range of outcomes in a clinical pathway. 
Nonetheless, it may suffice at an early stage to consider the 
main outcomes and to limit stratification into one or two 
  
Fig. 1 Didactic examples of cost-consequence analyses: a) equivalence 
(symmetry with respect to both axes); b) more cost-effective than the 
benchmark. 
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groups. One approach is to use rarefied Markov models that 
use a minimum number of states and transitions according 
to data availability.  
Such an approach was taken by Dong and Buxton with total 
knee replacement (TKR) whereby knee patients are divided 
into three groups, those who have had a primary TKR oper-
ation with no complications, and those who have minor or 
serious complications. Following the primary TKR, patients 
with complications may require a revision or other treat-
ments. In the Markov model this requires probabilities be-
tween these states and various additional complication 
states or death, as determined from the clinical literature or 
best estimates. A comparison of computer-assisted (image-
guided) and standard total knee replacement was performed 
using this basic model with nine states [12]. 
In a further study by one of the authors [MC], a four state 
model was used to perform a „what-if‟ analysis for a device 
that aimed at promoting healing in diabetic foot ulcer. The 
model included a diabetic no-wound state, a wounded (ulce-
rated) state, an amputee state, and dead. This is a simplifica-
tion of a more sophisticated model that would include strati-
fying patients into low and high risk and to consider 
multiple ulcerations and amputations with different proba-
bilities. The value proposition of the device was examined 
by increasing the probability of transition from the wounded 
to the no-wound state e.g. the healing rate, and decreasing 
the probability of amputation [13]. 
IV. CONCLUSIONS 
According to the WHO definition, health technologies 
include both drugs and biomedical devices. Nonetheless,  
HTA methods can be difficult to apply to biomedical devic-
es particularly in early stage assessment. The MATCH 
experience shows that it is possible to develop specific 
methods to assess biomedical devices at an early stage. In 
particular AHP is an effective method with which to elicit 
user needs and Markov models with a minimal number of 
states can be used to perform „what-if‟ analyses at an early 
stage. 
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